Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Inclusion Criteria:

Estrogen or progesterone receptor positive stage IIIb/IV non-small cell lung cancer
Eligible patients will have stable disease on erlotinib monotherapy at FDA- approved doses after a minimum duration of erlotinib therapy of 2 months
18 years or older
ECOG Performance Status ≤2
Adequate Organ Function Requirements
Adequate coagulation function
Postmenopausal status in female patients is required and is defined as no menstrual periods for 12 month or surgical menopause
All patients must sign a written informed consent.

Exclusion Criteria:

Pregnant or breast-feeding women will not be entered on this study
Patients who are currently receiving another investigational drugs
Patients who are currently receiving other anti-cancer agents.
Hormone replacement therapy will not be allowed and have to be stopped 1 month prior to entry into the study
Patients who have an uncontrolled infection.
Patients receiving less than 100mg/day of erlotinib
Patients with evidence of progression after 2 months of erlotinib monotherapy.
Patients with a history of bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency) or long-term anticoagulant therapy (other than antiplatelet therapy).
Patients with a history of hypersensitivity to active or inactive excipients of fulvestrant (i.e. castor oil or Mannitol).
Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.